PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
复制标题
PD-1/PD-L1 检查点抑制剂免疫疗法治疗恶性胸膜间皮瘤：病例系列和文献综述。
DOI：
10.1016/j.cllc.2020.05.012
复制
发表时间：
2020
影响因子：
3.6
通讯作者：
J. Neal
中科院分区：
文献类型：
--
作者：
Maggie Y. Zhou;N. Joshi;K. P. Raj;H. Wakelee;J. Neal
恶性胸膜间皮瘤（MPM）是一种罕见的侵袭性肿瘤，起源于胸膜间皮层。 MPM 是最常见的间皮瘤类型，约占病例的 90%。 1 治疗包括手术切除、放疗和全身化疗。大多数患者要么患有晚期疾病，要么由于合并症或高龄而不适合手术。预后普遍较差，总体 5 年生存率为 8.5% 2，未经治疗的 MPM 的中位总体生存期不到一年。 3 MPM 的组织学亚型包括上皮样亚型、肉瘤样亚型（包括促纤维增生性和淋巴组织细胞亚型）和混合型（双相型）。上皮样组织学与更良好的预后和治疗反应相关，发生在 50% 至 60% 的患者中。肉瘤样亚型对治疗产生反应的机会较低，发生在 20% 的患者中。 4 与间皮瘤生存率改善相关的其他重要预测因素包括女性、年龄 45 岁以下、除手术外的化疗和放疗与单纯手术的对比、无吸烟史以及无已知的石棉接触史。 5
Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm that arises from the mesothelial lining of the pleura. MPM is the most common type of mesothelioma, accounting for about 90% of cases. 1 Treatments include surgical resection, radiation, and systemic chemotherapy. Most patients present with either advanced disease or are not surgical candidates as a result of comorbidities or advanced age. Prognosis is generally poor, with an overall 5-year survival rate of 8.5% 2 and median overall survival for untreated MPM of less than a year. 3 Histologic subtypes of MPM include epithelioid, sarcomatoid (including desmoplastic and lymphohistiocytic variants), and mixed (biphasic). Epithelioid histology is associated with a more favorable prognosis and response to therapy, occurring in 50% to 60% of patients. The sarcomatoid subtype has a lower chance of response to therapy and occurs in 20% of patients. 4 Other significant predictors associated with improved survival in mesothelioma include female gender, age under 45, chemotherapy and radiotherapy in addition to surgery versus surgery alone, no smoking history, and no known asbestos exposure history. 5
DOI：
--
发表时间：
1987
期刊：
The American journal of pathology
影响因子：
--
作者：
Moalli,PA;MacDonald,JL;Goodglick,LA;Kane,AB
通讯作者：
Kane,AB